Micrus Endovascular is the only publicly traded company focused on strokes.
Diabetes Drug Wins Approval, Helps the Competition
The approval of Novo Nordisk’s diabetes drug Victoza has led to an unintended benefit for a competitor.
[OneMedForum] Biomoda’s Platform for Early Cancer Detection
Biomoda’s CyPath diagnostic assay is based on molecular marker technology originally developed at the Los Alamos National Laboratory.
Genomic Health’s Colon Cancer Test Goes Worldwide
Genomic Health, a developer of genomics-based diagnostic tests, announced on Thursday the worldwide availability of its Oncotype DX Colon Cancer Test.
Healthcare Conference Updates: AUXL, CTIC, CYTX, KERX
Below are some updates and developments from the past week.
[OneMedForum] NuVue Therapeutics’ Multi-Step Approach to Cancer Therapy
NuVue Therapeutics is commercializing a site-specific regimen of cancer therapy for soft tissue tumors.
[OneMedForum] Immunocellular Therapeutics
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
Keryx Biopharma: Well-Funded Comeback Story with Multiple Catalysts
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
